Results 211 to 219 of about 8,771 (219)

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Lancet, The, 2019
Désirée M Van Der Heijde, Atul Deodhar, Mrcp, Filip E Van Den Bosch   +2 more
exaly  

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Lancet, The, 2018
Bernard Combe, Andrea Rubbert-Roth, Mohamed-Eslam F Mohamed Rph   +2 more
exaly  

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2018
Gerd R Burmester, Joel M Kremer, Filip E Van Den Bosch   +2 more
exaly  

Upadacitinib for ulcerative colitis

Lancet, The, 2022
exaly  

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials

Clinical Pharmacology in Drug Development, 2019
Mohamed-Eslam F Mohamed Rph, Ahmed A Othman, Fcp   +1 more
exaly  

Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib

British Journal of Clinical Pharmacology, 2017
Mohamed-Eslam F Mohamed Rph, Ahmed A Othman, Fcp   +1 more
exaly  

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis

New England Journal of Medicine
Andrea Rubbert-Roth, Ellen-Margrethe Hauge, Tomonori Ishii   +2 more
exaly  

Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study

EClinicalMedicine
Thierry Passeron, Khaled Ezzedine, Heidi Camp   +2 more
exaly  

Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies

International Immunopharmacology
Cong Dai
exaly